Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Sanofi-Aventis Expands Rimonabant Diabetes Program With Multiple Trials

  • News

Executive Summary

Sanofi-Aventis is expanding its Zimulti (rimonabant) diabetes program after clinical study results showed the drug's effectiveness in reducing HbA1c is comparable to oral anti-diabetics

You may also be interested in...



Sanofi Outlines Plans To Establish Lantus As Leading Worldwide Anti-Diabetic

Sanofi-Aventis aims to establish its long-acting insulin Lantus (insulin glargine injection) as the leading anti-diabetic worldwide by marketing it for combination use as well as a stand-alone product

Sanofi Outlines Plans To Establish Lantus As Leading Worldwide Anti-Diabetic

Sanofi-Aventis aims to establish its long-acting insulin Lantus (insulin glargine injection) as the leading anti-diabetic worldwide by marketing it for combination use as well as a stand-alone product

FDA First-Cycle Approval Rate Is Silver Lining In Cloud Of Low NME Count

Three-quarters of the new molecular entities cleared by FDA in 2007 were approved on the first review cycle, a high for this decade and a positive note to counterbalance the record low number of NMEs approved

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month

Supplemental Filings: FDA Expands In-Person Meeting Eligibility Again; Marks Suggests Sponsors Invite Foreign Regulators To FDA Meetings

Diabetes Drugs: US FDA Proposes Hypoglycemia Efficacy Endpoints, With Limits

FDA, Medicare And The Future Of Coverage With Evidence Development For Accelerated Approvals

See All
UsernamePublicRestriction

Register

PS048828

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By